Cargando…
The Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival
BACKGROUND: Fat grafting is an increasingly popular method of augmentation/reconstruction of soft tissue defects. However, the clinical unpredictability and high resorption rates of the grafts remain problematic. Cellular stress from the harvest and the ensuing ischemic episode may be the cause of t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977134/ https://www.ncbi.nlm.nih.gov/pubmed/27536485 http://dx.doi.org/10.1097/GOX.0000000000000821 |
_version_ | 1782446975569887232 |
---|---|
author | Filson, Simon A. Keren, Aviad Goldstein, Nyra Ullmann, Yehuda |
author_facet | Filson, Simon A. Keren, Aviad Goldstein, Nyra Ullmann, Yehuda |
author_sort | Filson, Simon A. |
collection | PubMed |
description | BACKGROUND: Fat grafting is an increasingly popular method of augmentation/reconstruction of soft tissue defects. However, the clinical unpredictability and high resorption rates of the grafts remain problematic. Cellular stress from the harvest and the ensuing ischemic episode may be the cause of this. Cellular stress activates the p38 mitogen–activated protein kinase (MAPK) signaling pathway. In response to cellular stress, the p38 pathway can lead to apoptosis and can negatively regulate cell proliferation. Inhibition of p38 in ex vivo experiments has been shown to promote the expansion of human cord blood hematopoietic stem cell and improve the adipogenesis process through its upstream regulator, Shp2. Because of its wide-ranging cell regulation and antiinflammatory properties, large-scale clinical trials using p38 inhibitors are also currently being performed, especially for therapeutic effect in chronic obstructive pulmonary disease and asthma. The rationale for our study was that the treatment of fat grafts with p38 inhibitor would (a) prevent apoptosis of adipose-derived stem cells in the fat grafts, (b) increase adipose-derived stem cells proliferation, and (c) stimulate the release of several angiogenic factors and promote revascularization. METHODS: Clinical and histological testing was performed on 5 fat-transplanted (1 mL) CD-1 nude mice compared with the test group of 5 mice, which were injected with a p38 MAPK inhibitor at 1, 3, 6, and 9 days after the fat transplantation. RESULTS: The weights and volumes of the control group grafts were significantly higher than those of the p38 MAPK inhibitor–treated grafts. Average volume resorption was 36% in the control group and 92% in the test group. Histological evaluation of the grafts revealed significantly improved integration, with a significant reduction of fibrosis and inflammation in the control group versus the treated group. CONCLUSIONS: This preliminary study suggests that as opposed to our hypothesis, inhibition of p38 significantly increases fat graft resorption. The dramatic effects observed in our study may suggest that p38 may act differently on the numerous cell types that constitute the fat graft, and further investigation is necessary. |
format | Online Article Text |
id | pubmed-4977134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-49771342016-08-17 The Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival Filson, Simon A. Keren, Aviad Goldstein, Nyra Ullmann, Yehuda Plast Reconstr Surg Glob Open Experimental BACKGROUND: Fat grafting is an increasingly popular method of augmentation/reconstruction of soft tissue defects. However, the clinical unpredictability and high resorption rates of the grafts remain problematic. Cellular stress from the harvest and the ensuing ischemic episode may be the cause of this. Cellular stress activates the p38 mitogen–activated protein kinase (MAPK) signaling pathway. In response to cellular stress, the p38 pathway can lead to apoptosis and can negatively regulate cell proliferation. Inhibition of p38 in ex vivo experiments has been shown to promote the expansion of human cord blood hematopoietic stem cell and improve the adipogenesis process through its upstream regulator, Shp2. Because of its wide-ranging cell regulation and antiinflammatory properties, large-scale clinical trials using p38 inhibitors are also currently being performed, especially for therapeutic effect in chronic obstructive pulmonary disease and asthma. The rationale for our study was that the treatment of fat grafts with p38 inhibitor would (a) prevent apoptosis of adipose-derived stem cells in the fat grafts, (b) increase adipose-derived stem cells proliferation, and (c) stimulate the release of several angiogenic factors and promote revascularization. METHODS: Clinical and histological testing was performed on 5 fat-transplanted (1 mL) CD-1 nude mice compared with the test group of 5 mice, which were injected with a p38 MAPK inhibitor at 1, 3, 6, and 9 days after the fat transplantation. RESULTS: The weights and volumes of the control group grafts were significantly higher than those of the p38 MAPK inhibitor–treated grafts. Average volume resorption was 36% in the control group and 92% in the test group. Histological evaluation of the grafts revealed significantly improved integration, with a significant reduction of fibrosis and inflammation in the control group versus the treated group. CONCLUSIONS: This preliminary study suggests that as opposed to our hypothesis, inhibition of p38 significantly increases fat graft resorption. The dramatic effects observed in our study may suggest that p38 may act differently on the numerous cell types that constitute the fat graft, and further investigation is necessary. Wolters Kluwer Health 2016-07-15 /pmc/articles/PMC4977134/ /pubmed/27536485 http://dx.doi.org/10.1097/GOX.0000000000000821 Text en Copyright © 2016 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | Experimental Filson, Simon A. Keren, Aviad Goldstein, Nyra Ullmann, Yehuda The Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival |
title | The Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival |
title_full | The Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival |
title_fullStr | The Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival |
title_full_unstemmed | The Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival |
title_short | The Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival |
title_sort | opposite expected effect of p38 inhibitors on fat graft survival |
topic | Experimental |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977134/ https://www.ncbi.nlm.nih.gov/pubmed/27536485 http://dx.doi.org/10.1097/GOX.0000000000000821 |
work_keys_str_mv | AT filsonsimona theoppositeexpectedeffectofp38inhibitorsonfatgraftsurvival AT kerenaviad theoppositeexpectedeffectofp38inhibitorsonfatgraftsurvival AT goldsteinnyra theoppositeexpectedeffectofp38inhibitorsonfatgraftsurvival AT ullmannyehuda theoppositeexpectedeffectofp38inhibitorsonfatgraftsurvival AT filsonsimona oppositeexpectedeffectofp38inhibitorsonfatgraftsurvival AT kerenaviad oppositeexpectedeffectofp38inhibitorsonfatgraftsurvival AT goldsteinnyra oppositeexpectedeffectofp38inhibitorsonfatgraftsurvival AT ullmannyehuda oppositeexpectedeffectofp38inhibitorsonfatgraftsurvival |